Online inquiry

IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4718MR)

This product GTTS-WQ4718MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL21 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001207006.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4718MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11084MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ2993MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ1794MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ4195MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ11611MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ14270MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ3765MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ1369MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW